Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- FDA Moves Against Unapproved Obesity Drugs
- The FDA has published a list of unapproved, "tainted," or "undeclared" weight-loss drugs that it wants off the market. The list includes rimonabant and sibutramine. Rimonabant was the active ingredient in Zimulti/Acomplia, the ill-fated obesity treatment that Sanofi-Aventis tried to get approved in the U.S. The FDA turned the application...
- Blog posts 2009-01-09
- Why Vivus's Qnexa Might Avoid the Obesity Drug Graveyard
- Vivus’s better-than-expected Phase III data with obesity drug Qnexa started the goldmine versus graveyard debate once again. In one corner: the folks who think obesity is the last frontier. In the other corner: the folks like BNET’s own Jim Edwards, who argues that obesity drugs are doomed to failure. by...
- Blog posts 2009-09-13
Additional Resources
- VIVUS: Dr. Linda D. Shortliffe joins VIVUS' Board of Directors.
- M2 PRESSWIRE-17 June 1999-VIVUS: Dr. Linda D. Shortliffe joins VIVUS' Board of Directors C1994-99 M2 COMMUNICATIONS LTD RDATE:160699 MOUNTAIN VIEW, CA -- VIVUS, (Nasdaq: VVUS) has named Linda M. Dairiki Shortliffe, M.D. professor at Stanford University School of Medicine and Chair...
- Research articles 1999-06-17
- VIVUS: Vivus responds to reports of "disappointing results" with MUSE (alprostadil)
- M2 PRESSWIRE-8 June 1998-VIVUS: Vivus responds to reports of "disappointing results" with MUSE alprostadil C1994-98 M2 COMMUNICATIONS LTD RDATE:050698 MOUNTAIN VIEW, CA -- VIVUS, Inc. (Nasdaq: VVUS) today responded to media reports about "disappointing results" data presented at the American Urological Association AUA annual...
- Research articles 1998-06-08
- VIVUS: VISX CEO and Wilson, Sonsini, Goodrich & Rosati Partner join the Vivus Board of Directors.
- M2 PRESSWIRE-18 March 1999-VIVUS: VISX CEO Mark Logan and Wilson, Sonsini, Goodrich & Rosati Partner Mario Rosati join the Vivus Board of Directors C1994-99 M2 COMMUNICATIONS LTD RDATE:170399 MOUNTAIN VIEW, CA -- VIVUS, Inc. (Nasdaq: VVUS) has named Mark Logan, Chairman,...
- Research articles 1999-03-18
- Vivus's Qnexa Drug Approval Makes It a Nice Trade
- Here are Wednesday's articles concerning Vivus Inc's VVUS FDA approval for Qnexa. I see this as a blockbuster drug candidate and good news for the nearly 40M Obese Americans. My only caution is later health problems as it uses some form of the fen-phen medication. This is a nice trade...
- External links 2009-09-10
- New Erectile Dysfunction Treatment Patent Granted to VIVUS
- MOUNTAIN VIEW, Calif.--BW HealthWire--March 24, 1999--VIVUS, Inc. (Nasdaq:VVUS) has been issued patent No. 5,886,039 for the "Method and Composition for Treating Erectile Dysfunction" by the U.S. Patent Office. This patent provides VIVUS with broad patent protection for the commercialization of ALIBRAtm, VIVUS' second-generation transurethral treatment for male erectile dysfunction ED.
- Research articles 1999-03-24
- VIVUS Announces MUSE 18-Month Post-Marketing Safety Data; Over 1 Million Prescriptions and 600,000 Patients Treated, Resulting in Only One Death Reported To FDA
- MOUNTAIN VIEW, Calif.--BW HealthWire--July 22, 1998--VIVUS, Inc. (NASDAQ:VVUS) today announced data from an 18-month post-marketing safety review of MUSER alprostadil. The VIVUS post-marketing surveillance program tracks spontaneous adverse events reported from commercial sales of MUSE. Since FDA approval in November 1996, over 1 million prescriptions for MUSE have been filled,...
- Research articles 1998-07-22
- VIVUS Announces Second Supplier of Alprostadil
- MENLO PARK, Calif.--BUSINESS WIRE--Jan. 8, 1996--VIVUS, Inc. (NASDAQ: VVUS) today announced that it has entered into a long-term supply agreement with Chinoin Pharmaceutical and Chemical Works Co., Ltd. for alprostadil, the drug substance used in VIVUS' anticipated first product, MUSE alprostadil.Chinoin is a Hungarian subsidiary of the French pharmaceutical company...
- Research articles 1996-01-08
- Vivus Signs International Marketing Agreement With Janssen
- MENLO PARK, Calif.--BUSINESS WIRE--Jan. 23, 1997--VIVUS, Inc. (NASDAQ:VVUS) today announced that the company has signed an international marketing agreement with Janssen Pharmaceutica International, a subsidiary of Johnson & Johnson. This agreement for MUSE alprostadil, VIVUS treatment for erectile dysfunction, covers China, multiple Pacific Rim countries excluding Japan,...
- Research articles 1997-01-23
- Class Action Suit Filed Against Vivus, Inc. and Its Officers and Directors Alleging Misrepresentations, False Financial Statements and Insider Trading
- SAN DIEGO--BUSINESS WIRE--Feb. 27, 1998--A class action has been commenced in the California Superior Court for San Mateo County on behalf of purchasers of Vivus, Inc. ("Vivus") common stock during the period May 15, 1997 to December 9, 1997 (the "Class Period"). The complaint charges Vivus and...
- Research articles 1998-02-27
- Weiss & Yourman Files Securities Fraud Class Action Against Vivus, Inc. and Certain of its Officers and Directors
- LOS ANGELES--BUSINESS WIRE--March 20, 1998--On March 16, 1998, a class action lawsuit was filed in the U.S. District Court for the Northern District of California by the law firm of Weiss & Yourman on behalf of purchasers of Vivus, Inc. ("Vivus" or the "Company") (NASDAQ: VVUS) common stock between May...
- Research articles 1998-03-20
- Vivus Announces Production Shortfall
- MENLO PARK, Calif.--BUSINESS WIRE--Dec. 10, 1997--VIVUS, Inc. (NASDAQ:VVUS) today announced that the Company will be unable to meet its production goals for the fourth quarter. This shortfall results primarily from the Company's efforts to expand its production capacity into its new 90,000 square foot plant. In an effort...
- Research articles 1997-12-10
- VIVUS Completes Special Protocol Assessment for Phase 3 Efficacy Studies and Reaches Agreement with the FDA on the Safety Study for Luramist
- MOUNTAIN VIEW, Calif. -- VIVUS, Inc. (NASDAQ: VVUS) announced today that it has successfully completed and reached agreement with the U.S. Food and Drug Administration FDA regarding the Special Protocol Assessment SPA for the phase 3 efficacy trials for Luramist, testosterone metered dose transdermal spray MDTS, for the treatment of...
- Research articles 2008-04-01
- VIVUS to Participate in Panel at the 2007 RBC Capital Markets Healthcare Conference
- MOUNTAIN VIEW, Calif. -- VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, vice president and chief financial officer of VIVUS will be presenting at the RBC Capital Markets Healthcare Conference.
- Research articles 2007-12-07
- VIVUS to Present at the 2008 Merrill Lynch Global Healthcare Conference
- MOUNTAIN VIEW, Calif. -- VIVUS, Inc. (NASDAQ: VVUS) a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Leland F. Wilson, President and CEO, will present an overview of the company at the 19th Annual Merrill Lynch Global Pharmaceutical, Biotechnology, and Medical Device Conference...
- Research articles 2008-02-01
- VIVUS Announces Closing of $65 Million Registered Direct Offering of Common Stock
- MOUNTAIN VIEW, Calif. -- VIVUS, Inc. (NASDAQ: VVUS) announced today that it has consummated the previously announced registered direct offering of 8,365,508 shares of its common stock to a select group of institutional investors at $7.77 per share. The offering resulted in net proceeds of approximately $63.4 million. The...
- Research articles 2008-08-06
- Vivus Files NDA for the Treatment of Erectile Dysfunction
- MENLO PARK, Calif.--BUSINESS WIRE--March 28, 1996--VIVUS, Inc. (NASDAQ: VVUS) today announced that the company has submitted a New Drug Application NDA to the FDA for the use of MUSE alprostadil in treating erectile dysfunction, commonly known as impotence.Leland F. Wilson, president and chief executive officer of VIVUS, said, "We are...
- Research articles 1996-03-28
- Rexahn, Vivus Believe the World Needs 2 More ED Drugs
- Two companies are developing new erectile dysfunction drugs, even though there's already three on the market and one of those -- Pfizer's Viagra -- is set to go generic between 2011 and 2013. Rexahn is developing a compound called Zoraxel and Vivus is developing Avanafil. Rexahn is...
- Blog posts 2009-02-12
- Vivus Beating Arena, Orexigen In Obesity Graveyard Race
- The race to produce a blockbuster anti-obesity pill -- a contest that no company has yet won -- got interesting this week with the news, via AP, that Arena Pharmaceuticals' data showed that its contender, lorcaserin, showed only 3.6 percent more effectiveness than a placebo. The FDA wants to see...
- Blog posts 2009-03-31
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
